View all veterinary jobs
VetSurgeon.org publishes a curated feed of veterinary news for practising veterinary surgeons, with a primary focus on the UK profession.
We select stories based on their practical relevance, clinical interest, or professional significance — filtering out noise so busy vets can stay informed quickly.
Our coverage includes:
We report across all areas of practice, including companion animal, farm, equine and exotic species.
Our editorial approach is deliberately selective and concise. We prioritise clarity and relevance over volume, aiming to make each story worth your time.
You can follow VetSurgeon News by subscribing to the daily, weekly or monthly email digest, or via our channels on Facebook and LinkedIn.
Hannah, who graduated from the RVC in 2015, was nominated for her dedication to excelling in first-opinion practice through her farm, small animal and equine work as a mixed animal vet in Aberystwyth.
She was selected from a field of more than 100 entrants by the award judges BVA President Malcolm Morley, President of the Royal College of Veterinary Surgeons (RCVS) Melissa Donald, Professor the Lord Trees, Zoetis National Veterinary Manager Jonny Lambert and last year’s winner of the award, Alex Davies.
Hannah said: “This is fantastic! I’m so pleased to accept this award.
"I want to say a huge thanks to my practice for giving me the freedom to explore my passions and enabling me to work with a wide of range of species.
"I want to particularly mention my mentors Dafydd, Phil and Kate, who inspired me to focus on what I love.”
BVA President Malcolm Morley said: “Hannah’s incredible enthusiasm and passion for her work as a mixed-practice vet really made her stand-out to us.
"She is excelling in her work across species, which is challenging enough, but she’s also doing it at a high level.
"It is great to recognise the contribution that Hannah and other first-opinion vets make to our profession."
The apple-flavoured, gastro-resistant granules can be mixed with dry feed to make administration easier for owners.
Animalcare says that up to 37% of leisure horses and 93% of race horses are reported to be affected by gastric ulcers1, for which the most prescribed treatment is omeprazole.
Equizol’s granule formulation has been developed to support owners who find syringe administration difficult or wasteful. It is presented in packs of 28 sachets, each containing sufficient omeprazole to treat 200 kg body weight. Owners mix the appropriate number of sachets into a small amount of the horse’s feed.
Animalcare Product Manager James Beaumont said: “Offering innovative product solutions which better meet our customer’s needs is our goal and Equizol is a perfect example. Our established equine healthcare range includes products for pain management, infusion therapy and microchips. Now, with the launch of Equizol, we are offering an innovative, easy-to-use and cost-effective solution to the common problem of gastric ulcers, based on tried and trusted omeprazole. We are delighted to add it to our range.”
Reference
The study1, which was conducted in collaboration with Plymouth University, sought to find out what influences owners to buy a flat-faced breed, and once this decision has been made, how they go about acquiring a puppy. The study surveyed owners of the top 10 most popular Kennel Club registered breeds in the UK, to compare how influences upon breed choice and purchasing processes differed between owners of flat-faced breeds and popular longer-faced breeds.
Appearance was found to be the number one reason owners purchase flat-faced breeds, attracted by their large, round, wide-set eyes, and flat rounded faces. However, such characteristics are linked with lifelong respiratory, eye and skin problems, and a reduced lifespan compared with longer-faced breeds.
Key influencing factors associated with the choice of a brachycephalic breed included:
When it came to buying a flat-faced dog, owners were:
Dr Rowena Packer, lead author of the study and Research Fellow at RVC, said: "With their small size and baby-like features, some people cannot resist the looks of a brachycephalic dog. With growing evidence that these breeds are faced with a range of chronic and severe health conditions directly linked with their appearance, it is of huge concern that many people drawn to these breeds prioritise a dog’s looks over their long-term health and wellbeing.
"Potential puppy buyers attracted to the appearance of these breeds should seriously consider whether they are emotionally and financially prepared to take on a breed with high risks of health complications, and consider whether alternative, lower-risk breeds would better fit their lifestyle."
Co-author of the study and Associate Professor of Animal Welfare at Plymouth University, Dr Mark Farnworth, said: "Owners must be aware that as puppy-buyers, they are consumers, and their choices affect not only the health of the puppy they purchase, but also the health of the breed more widely. If owners do not follow recommended processes when purchasing a puppy, for example those set out in BVA AWF & RSPCA ‘Puppy Contract’, unscrupulous breeders will be kept in business, and continue to profit from the breeding and sale of unhealthy dogs. Without consumer awareness, breed health improvements are not possible and the overall health of these breeds will likely decline."
Paula Boyden, Dogs Trust Veterinary Director said: "The increased popularity of breeds such as Pugs, French Bulldogs and English Bulldogs is a huge welfare concern, particularly as this research indicates that the health of the breed was not a major consideration for potential puppy buyers. Many people mistakenly believe that the breathing sounds these breeds often make are endearing traits, rather than an indication of respiratory problems associated with their conformation. Dogs Trust urges anyone thinking of getting a puppy to look beyond the appearance of a breed, understand the impact on health, research the seller and buy responsibly."
Researchers say that the French Bulldog is set to become the most registered dog in 2017, overtaking the Labrador Retrievers’ 27-year reign at the top. The study therefore makes a number of recommendations, including:
Photo: Wikipedia CC BY-SA 3.0 Credit: Cristorresfer
Jurox says Alfaxan Multidose is the bioequivalent to unpreserved Alfaxan, however the preserved formulation reduces the risk of microbial contamination, providing repeatable and reliable anaesthesia.
Alfaxan Multidose is available in two presentations of 10ml and 20ml, with the 20ml presentation priced at an equivalent price per ml as the current 10ml Alfaxan unpreserved presentation.
Jurox says there has been unprecedented interest in the new product, with the company taking pre-orders for the 20ml presentation from 60 different accounts at BSAVA this year.
Richard Beckwith, country manager at Jurox, said: "The introduction of Alfaxan Multidose to our anaesthesia and analgesia portfolio ensures that Alfaxan is more versatile than ever.
"The Alfaxan range continues to provide greater certainty and control during anaesthetic procedures, contributing towards better patient stability and a stress-free experience for the team."
For more information, visit www.alfaxan.co.uk, contact your local Jurox technical sales representative, telephone the customer services team on 0800 500 3171 or e-mail: info@jurox.co.uk.
If, as is predicted, social distancing methods need to be employed to reduce the spread of the virus, or clients find themselves having to self-isolate, video consultations may offer a way in which veterinary practices can continue to serve their clients, maintain animal welfare and, importantly, revenue.
VetHelpDirect's video consultation system, which was announced earlier this year, is still in the Beta testing phase, and the plan had been to roll out the full service in May.
Under the circumstances, however, the company has decided to offer the service to all practices immediately, free of charge for the next three months.
To use the video consultation service, you do need to subscribe to use VetHelpDirect, a service through which you can manage client reviews of your practice. That costs £38 per month, per practice and a further £16 for branch practices.
Susie Samuel, CEO of VetHelpDirect said: “The Coronavirus presents a very real business risk to veterinary practices and a health risk to staff.
"As cases increase, animal owners in quarantine will not be able to visit the vet when their animals become unwell. In these cases, veterinary practitioners will not be able to discuss an animal’s symptoms with their owner in person and could end up relying solely on telephone consultations which would most likely be conducted free of charge.
"Our video platform allows vets to collect payment for a consultation as usual, hold the consultation with the animal’s owner and if a pet needs to be seen, the owner could, in theory, drop it off at the surgery without making personal contact with the vet clinic staff."
VetHelpDirect has not yet decided precisely what the video consultation service will cost after the free period, but it is likely to be around the £20 per month mark. In addition, there is a 4.8% transaction fee.
For more information, contact Susie Samuel susie@vethelpdirect.com
COMMENTDespite the emergence of a number of online-only, limited-service veterinary video consultation providers, it seems like very few, if any independent practices are yet offering this service. There is a danger that unless they do so very soon, they will find themselves at a real disadvantage to the first movers. But there is still time; according to VetHelpDirect's research, 38% of people say they would use video consultations with their own vet but only 7% with a vet they don't know..
It strikes me that now is a very good moment to start offering clients this kind of service, because regardless of government advice, there will doubtless be some who will want to avoid a trip to the vets whilst the outbreak persists.
European Specialist in Veterinary Dentistry Lisa Milella has revealed in an interview with the Sunday People that she has been diagnosed with motor neurone disease, a condition which few people survive for more than 2-5 years.
It's hard to imagine anything much worse than being told in advance when your appointment with the Grim Reaper is booked, and for many the temptation might be just to give up there and then. Not Lisa. She embarked on the most extraordinary mission to fulfill ten of her life's ambitions.
The day after her diagnosis last August, she closed her veterinary practice in Byfleet. In December, she went sledging with huskies in Norway. In January, she flew to Borneo to carry out dental surgery on an orangutan. Three days later, she visited International Animal Rescue in Java and trained vets there to carry out dental work on slow lorises. She then celebrated her 40th birthday surrounded by friends and family in February. In May, she headed out to Peru to visit the Inca trail and the Amazon rainforest. From there, it was on to the Galapagos Islands. Then last week she went to India, where she trained another team to perform dental surgery on bears, and fulfil the 8th and 9th ambitions on her list, which were to operate on a leopard and a tiger.
Lisa closed her interview in the Sunday People saying: "I'm never going to get better and today is as strong as I'm ever going to be. You've got to make the most of now and not worry about tomorrow. Go out there and do it. You're never going to have that time again."
Oh. One other thing. Lisa's 10th wish was to get 100 strangers to donate £100 to International Animal Rescue. I hope you'll join me: https://www.justgiving.com/Lisa-Milella-100/
Salmoporc gives protection against Salmonella Typhimurium and its monophasic variants. It is administered orally to piglets and through subcutaneous injection in sows.
According to the company, Salmoporc is the only live, attenuated salmonella vaccine licensed for pigs in the UK and Ireland.
Ceva says salmonella in UK and Irish herds is the highest in the EU, with a prevalence of 19.5% and 17.5% respectively. It is particularly difficult to control in outdoor herds since the bacteria can survive in soil for a year, even longer in dried dung and has been detected in fields two years after being vacated by pigs.
Outdoor bred, or reared, pigmeat accounts for 12% of retail sales and the majority of this is processed.
Dr Rike Schmelz from Ceva said: "Salmonella is an increasing problem on pig farms and the bacteria are transmitted through breeding pyramids which eventually supply finishing pigs. Clinical cases of diarrhoea often occur after weaning and tend to be treated with antibiotics."
Rike added: "The monophasic variant of S. Typhimurium is already multi-drug resistant and vaccinating pigs can help farmers to substantially reduce their use of expensive antibiotics. In addition, with the removal of zinc oxide at therapeutic levels from the feed in mid-2022, salmonella and other enteric diseases are likely to become more apparent."
Ceva says that by immunising their pigs against S. Typhimurium, farmers will gain an economic benefit from lowered mortality and improved daily liveweight gain (DLWG) among their pigs.
In independent trials at the University of Ghent in Belgium, between three and 29 weeks, vaccinated piglets from three herds gained between 30g and 39g, significantly more per day than unvaccinated controls.
Trials in Germany have shown that, with vaccination of sows and gilts at the top of the breeding pyramid, combined with a competent hygiene programme, it is possible to eliminate salmonella from the supply chain.
Renutend contains primed mesenchymal stem cells (MSCs) which Boehringer says are specifically targeted to reduce scar tissue formation so horses can return to the intended level of performance, with a reduced risk of re-injury1.
According to the company, a single dose decreases scar tissue formation with consistent and proven results 2.
RenuTend is administered by intralesional injection and complements Boehringer Ingelheim’s other equine stem cell product Arti-Cell Forte, which is authorised to treat mild to moderate recurrent lameness associated with non-septic joint inflammation in horses.
RenuTend will be available in September this year.
In the meantime, Boehringer is encouraging veterinary surgeons to register their interest with their BIAH representative or call 01344746960 in order to get updates or product information as soon as it becomes available.
References
The flowchart, which was produced in partnership with the National Animal Health and Welfare Panel (NAHWP) and with support from Dogs Trust, outlines what vets should consider when a client presents an animal with a pet passport and aim to help them navigate client confidentiality, how to report concerns of illegal imports, and an overview of how local authorities are likely to respond.
The Association says that in recent years, vets have mentioned finding it 'difficult' or 'very difficult' to report concerns to Trading Standards in the BVA Voice of the Veterinary Profession surveys. Other concerns included breaching client confidentiality, a lack of proof or sufficient evidence to investigate, a perceived lack of interest from local authorities if a case was reported, and uncertainty about whom to contact and how to report suspicions.
Findings released by Dogs Trust earlier this week show broadly similar concerns about reporting suspected illegal pet import cases.
BVA and NAHWP have issued the following advice for vets:
Report any suspicions that the animal in your care does not comply with Pet Travel Scheme requirements to your Local Authority Animal Health Function – either Trading Standards or Environmental Health Services.
Find out how to contact your local authority via a pre-agreed number for your practice. Find a direct contact number for your local Trading Standards or call Citizens Advice Consumer Helpline on 03454 04 05 06, who will refer you directly to the relevant local authority.
Note this number down on the joint BVA and NAHWP compliance flowchart and put up the poster in visible locations around your practice for staff to refer to.
BVA is also in talks with local authority forums in Wales and Scotland and the Department of Agriculture, Environment and Rural Affairs in Northern Ireland to launch similar guidance and compliance resources for vets in the devolved administrations.
BVA President Daniella Dos Santos said: "Veterinary teams can often be the first to suspect that an animal may have been illegally imported when an owner takes their pet for its first check-up. But our surveys have identified a compelling need for clearly defined routes and mechanisms for vets to more easily report suspected cases of illegal import.
"Our flow chart and supporting guidance aim to empower vets to report any such cases, thus helping to tackle the scourge of illegal importation and protecting animal welfare, both of the imported dogs and the larger canine population in the UK.
"I would encourage veterinary teams to put up the poster in their practices and use it to help report any suspicions to relevant authorities with ease."
The flowchart is available as a pull-out poster in this week’s Vet Record and can also be downloaded along with accompanying guidance notes here: www.bva.co.uk/illegalimportguidance
The website has been redesigned to help pet owners improve their understanding of the disease and support their commitment to treating their pet, thus improving the survival rates of diabetic pets.
The site includes videos which show how to give insulin injections to dogs and cats. There are also links to the Pet Diabetes Tracker App, which helps owners of diabetic pets monitor and record their pets’ progress. There are also tools to help pet owners build glucose curves they can share with their veterinary practice, and FAQs that will answer their main concerns.
The company is also offering additional support to help veterinary practices raise awareness of pet diabetes in the form of staff training and a Pet Diabetes Month Resource Pack.
Caroline Darouj, Senior Product Manager at MSD Animal Health said: "Pet diabetes continues to rise in the UK1,2 due to the growing prevalance of obesity in our pets. Research has shown that up to 20% of diabetic pets die, or are euthanised, within a year of diagnosis3. Many of these early deaths however, are avoidable and effective management can result in good outcomes in most pets. A diabetes diagnosis should not be a life sentence for our pets.
"This campaign and new website will make a big difference, giving practices the tools to engage pet owners, provide treatments plans and explain effective disease management. Diabetes is a disease with many elements that can feel overwhelming for pet owners so it’s vital that all veterinary practice team members have the right resources to be able to advise and support them so their pets can lead long and happy lives."
To sign up for a pack practices should go to www.msd-animal-health-hub.co.uk/PDM
Pfizer Animal Health has launched Zylexis for horses, the first and only immunomodulator licensed in the UK to reduce the clinical signs of equine respiratory disease associated with over-crowding and stress.
Zylexis contains inactivated parapox ovis virus (iPPOV), a super-antigen which Pfizer says boosts a horse's immune system to reduce the effects of infectious respiratory disease1,2 - bridging the gap between potential and performance.
According to the company, Zylexis acts by stimulating the horse's non-specific immune system, inducing antiviral interferons and interleukins and stimulating innate immune cells. In this way it bridges the gap until the horse's adaptive immune system can develop a pathogen-specific response.3-5
Pfizer highlights research which has shown a 40.3% reduction in the clinical signs and duration of respiratory disease in young horses under conditions of crowding and stress and a significant reduction of purulent nasal discharge when using Zylexis.6,7 No local or systemic adverse events were observed in a 999 dose study.8
Wendy Talbot, National Veterinary Manager at Pfizer, said: "Zylexis has been licensed in the States and in Germany for a number of years. We believe Zylexis plays a pivotal role in helping to minimise the severity of respiratory disease outbreaks in these countries, therefore helping to maintain performance potential. It's a very welcome addition to the medicine box of UK vets."
The administration of Zylexis is recommended as a course of three single dose intramuscular injections on days 0, 2 and 9. The first dose should be administered shortly before the over-crowding or stressful situation.
Virbac has has announced the launch of Buprevet, a buprenorphine-based, injectable solution indicated for the potentiation of sedative effects of centrally-acting agents in dogs and for use in cats and dogs as part of a multimodal approach to analgesia.
Buprevet is presented in a 10 ml multi-dose bottle which can be broached up to 25 times and can be open for up to 28 days.
Sarah Walker MRCVS, Product Manager, said: "Buprenorphine is a potent, high affinity, synthetic opioid agonist which forms a key element of practice anaesthetic protocols and complements our existing anaesthetic range. Its potentiation effects means less sedation is needed in the pre-medication and in the anaesthesia, facilitating smoother recoveries with more comfortable patients."
"Buprenorphine is a tried and trusted solution for analgesia in many practices. Buprevet can be given pre-operatively to allow analgesia during and after surgery. It works effectively as part of a pre-emptive approach to analgesia, alongside products such as Inflacam and Carprox in our NSAIDs range."
Lead author Professor Clare Rusbridge, Chief of Neurology at Fitzpartick Referrals, conducted the study because of a lack of clarity on the recognition and diagnosis of the clinical signs associated with CM as opposed to syringomyelia (SM).
CM is an abnormality in the skull, making it smaller, and impacting on the brain to alter the flow of cerebrospinal fluid; this results in pain and a collection of fluid pockets within the spinal cord. These fluid pockets are commonly known as SM and over time can cause irreversible damage to a dog’s spinal cord. However it is not clear whether signs of pain in affected dogs are due to CM or SM or both.
To try to rectify this, Clare studied the medical records of all the cavalier King Charles spaniels diagnosed with CM-associated clinical signs presenting to her at Fitzpatrick Referrals over a five year period. She documented the historical and examination findings and related them to the MRI findings, including presence and size of the SM.
She found common signs in all dogs were vocalisation, spinal pain (neck, middle or lower back), reduced activity, reduced stairs or jumping ability, aversion to being touched or groomed, altered emotional state (described as being more timid, anxious, withdrawn or aggressive) and sleep disturbance.
A tendency to rub or scratch at the head or ears was common but was more likely in dogs with small or no SM suggesting that this may be a sign of head discomfort associated with CM. Head and ear rubbing was not associated with the presence of material within the middle ear (a condition which is also common in this breed and often given the acronym PSOM).
The only signs that were specific to SM were phantom scratching, scoliosis (twisted spine) and weakness and these were only present when the SM was large (at least 4mm wide).
Clare says this study is important because it suggests that CM alone is a cause of pain in many dogs. The aim now is to use the information gained in this study to develop a questionnaire to determine risk of CM and monitor the response to clinical signs.
Photo: Charlie on a bad day
Baycox Iron Injection is indicated for the concurrent prevention of clinical signs of coccidiosis (such as diarrhoea) in neonatal piglets on farms with a confirmed history of coccidiosis caused by Cystoisospora suis, and the prevention of iron deficiency anaemia.
Professor Nicole Kemper, Director of the Institute for Animal Hygiene, Animal Welfare and Farm Animal Behaviour at the University of Veterinary Medicine Hannover in Germany said: "Piglets go through intense handling in their first days of life. While this is done to give them a better start to life and protect them from disease, it can also cause a lot of stress. Measures to reduce the need for piglet handling can make an important contribution to enhancing piglet well-being in the farrowing pen."
Octavio Orlovsky Eckhardt, Head of Species Marketing Swine at Animal Health, Bayer said: "A combination therapy that can effectively address these concerns with reduced handling can make a real difference for pig health and well-being.
"At the same time, farmers and workers can benefit from the reduced labour. For example, on a 1,000 sow farm, the reduced complexity is estimated to save up to one full work day every month."
For more information on Baycox Iron Injection, contact your local Bayer Animal Health representative.
The Adaptil Diffuser has been renamed the Adaptil Calm Home Diffuser, the Adaptil Collar has been renamed Adaptil Calm On-the-Go Collar, Adaptil Spray is now called Adaptil Transport and Adaptil Tablets are now called Adaptil Express.
The new products are split into three colour-coded groups. In blue packaging, Adaptil Calm Home Diffuser is designed to help dogs stay calm in recurring situations at home, including staying alone, loud noises and visitors. It comes as a 30-day starter kit containing a diffuser and refill, and lasts for 30 days.
Adaptil Calm On-the-go Collar is for use when dogs face fearful situations outdoors. It is available in two collar sizes (small to fit necks up to 37.5cm and large to fit necks up to 62.5cm) and it lasts for four weeks.
Adaptil Transport comes in yellow packaging and is designed to make travel and visits to the vet less stressful. It is available in 60ml and 20ml bottles.
Adaptil Calm Home Diffuser, Adaptil Calm On-the-Go Collar and Adaptil Transport all contain dog appeasing pheremones to help dogs feel calm and relaxed.
The last product in the new range is Adaptil Express, which comes in green packaging. Adaptil Express is an oral supplement which Ceva says provides a fast, calming effect for dogs faced with occasional challenging events such as thunderstorms and fireworks. The non-pheromone tablets, which come in packs of 10 or 40 tablets, combine GABA and amino acids and can be given with or without food.
Abigail King, product manager for Adaptil, said: "80% of pet owners state that their dog gets stressed during challenging situations both inside and outside the home and during specific occasions such as travelling, fireworks and thunderstorms1. Adaptil’s new product range caters for all these eventualities and the eye-catching branding and packaging clearly indicates which product should be used for each challenging occasion to aid owner compliance and help dogs feel calm and relaxed at all times."
For further information, visit www.adaptil.com/uk.
Kruuse is to launch a new Manuka honey dressing at BEVA 2011 in September.
Kruuse says that honey has been used as a topical anti-microbial agent and dressing for over 2000 years, and that honey derived from the nectar of the Manuka tree (Leptospermum scoparium) has its own unique chemical properties. Manuka honey contains glucose oxidase imparted by the bees during its collection and storage. This enzyme facilitates low level release of hydrogen peroxide when in the presence of wound exudates and thus supports cellular proliferation and metabolism through an antioxidant effect. The high sugar and low pH content creates a high osmotic potential which gives honey excellent debridement and anti-inflammatory properties.
The company says that one of the biggest difficulties with the use of honey in wound dressings is ensuring that once applied it stays over the wound area. Many attempts to coat dressings have been unsuccessful; often the active honey ingredient is left within the packaging severely reducing the effectiveness of the dressing. Kruuse says its Manuka dressings have the active honey impregnated 'within' the dressing, which ensures precise and easy application even if wearing surgical gloves.
The Kruuse Manuka dressings range comes in impregnated adherent (Kruuse Manuka AD), non-adherent dressing (Kruuse Manuka ND) and 15g tube of Manuka G. Each dressing comes in 3 sizes 5x5 cm , 10x12.5 cm and the KRUUSE Manuka roll (10x100 cm) a unique product ideal for large vertical wounds. E.G. Equine forelimb.
Kruuse also says that the antimicrobial potency in Manuka honey is rated by a standardised rating known as Unique Manuka Factor (UMF). The higher the UMF the better the antimicrobial effect. A minimum UMF of 10 is required to ensure sufficient effect in the wound environment, Kruuse Manuka Honey Wound Dressings have a Unique Manuka Factor of 15.
There is a restricted annual supply of Manuka honey as this unique product supply is controlled by a small number of producers in New Zealand. Many current honey products available use blends of Manuka honey with other poorer quality honey, these are often less effective. Kruuse Manuka uses 100% Manuka honey in all its dressings with the profits of the sale being returned directly to the Maori tribe that oversee the production of Manuka honey.
Andrew Groom, Managing Director Kruuse UK Ltd. said: "I am very excited that we have been able to secure a direct connection to supply this unique product with the knowledge that the Maori suppliers will see the returns for generations to come whilst this new range of dressing will add huge versatility for day to day wound management!"
Ceva says the adverts, which will air on Channel 4 and Channel 4 partner channels until 20th January, will reach 15 million people. That might prove a conservative estimate though, because the Adaptil advert on YouTube has already had over 800,000 views, whilst the Feliway advertisement has had very nearly as many.
In addition, Adaptil has partnered with The Times to support its 'Walking the Dog' podcast series hosted by radio presenter and journalist Emily Dean.
During the podcasts, Emily talks with celebrities like Noel Fitzpatrick, Jimmy Carr, Rob Bryden and Jonathan Ross as they walk their dogs. An Adaptil advert airs at the start, middle and end of each podcast.
You can hear the podcasts on itunes here: https://itunes.apple.com/gb/podcast/walking-the-dog-with-emily-dean/id1220510307
Abigail King, behaviour product manager at Ceva Animal Health said: "Our new TV advertising campaigns and podcast partnership will boost awareness of both Adaptil and Feliway throughout the festive period and into January, when changes to routine, visitors in the household and loud noises from Christmas crackers and fireworks can challenge even the most laid-back pet."
For more information, visit: www.adaptil.com or www.feliway.com.
The plan is designed to help mimic the way cats eat in the wild and so provide them with both physical and mental stimulation. It also encourages cats to hunt, explore, climb and play – activities which boost cats’ positive behaviour and wellbeing.
Developed by feline behaviour specialist Dr. Sarah Ellis and Dr. Lizzie Rowe at International Cat Care, the plan is also designed to help to prevent overeating and promote a balance between energy intake and energy output, in order to avoid weight gain, as well as encouraging weight loss in overweight cats.
It is estimated that there are 10 million pet cats in the UK1 and the charity points to data which suggests that 39 – 52% of them are overweight or obese2,3, something which is a major health and welfare issue4-9, and can ultimately lead to early death10.
The charity says research shows that current feeding practices are contributing to this obesity epidemic, with a number of factors associated with a cat’s modern lifestyle leading to overeating. For example, most cats need little or no exertion to obtain their food, making it more likely that the calories they take in through eating will outweigh the calories they use up through exercise (leading to weight gain). Furthermore, the way we feed our cats generally does not match the lifestyle they were designed for, resulting in a lack of mental stimulation and reduced opportunity to express natural, instinctive hunting behaviours. This can lead to boredom, apathy, anxiety, frustration and stress in cats, resulting in reduced wellbeing and potentially the development of problem behaviours.
Sarah said: "By making a few simple changes to the way we feed our cats, we can help them to live longer, healthier and happier lives."
The plan recommends:
A detailed version of the feeding plan, along with the full report behind the development of the plan, can be found on International Cat Care’s website:
https://icatcare.org/advice/general-care/keeping-your-cat-healthy/feeding-your-cat-or-kitten
A short version of the feeding plan can also be found there.
Ms Evans was charged with causing or allowing a veterinary nurse colleague to order a prescription-only medicine from a practice supplier knowing that it was intended for human use, and made a false entry prescribing the medication on the clinical records of a cat belonging to her nurse colleague.
She was also charged with falsely recording details purporting to be the results of the blood tests on cat and then entering notes on the animal's clinical history which falsely indicated that there had been a meaningful result, and then indicating to the animal's owner that there had been a meaningful result, when in fact the tests had failed to produce any meaningful results.
The final charge was that her conduct in making the false entry for the prescription-only medication, and all elements of the second charge was dishonest and misleading.
Ms Evans admitted the first charge on the basis that she had allowed rather than caused the order to be made, all the other facts of this charge were admitted.
She admitted the second charge on the basis that she had failed to inform the cat’s owner of the test results, all the other facts of this charge were admitted.
She also admitted that elements of her conduct had been dishonest and misleading.
Having found the charges proven by Ms Evans’ admissions, the Committee considered whether her admitted actions and conduct amounted to serious professional misconduct.
Ms Evans, through her legal counsel, accepted that the admitted charges passed the threshold for serious professional misconduct, though that question still needed to be determined independently by the Committee.
The Committee found that Dr Evans’ conduct had breached several key parts of the Code of Professional Conduct and its supporting guidance, particularly around honesty and integrity.
It also found aggravating factors in this case, including the risk to human health by allowing the prescription-only medication to be ordered knowing it was for human use, the abuse of her professional position, the breach of client trust, the potential adverse impact on the welfare of the cat for whom she falsified the blood test records, and the potential adverse impact on the welfare of the cat for whom she had falsely recorded the prescription-only medicine.
The Committee found no mitigating factors relating to the facts.
Paul Morris, chairing the Committee and speaking on its behalf, said in relation to the first charge: “In the Committee’s view, this irresponsible approach to a prescription-only medicine risked human health, potentially compromised an animal’s welfare, since the clinical record suggested the cat had been given Fluconazole when it had not, constituted an abuse of the trust placed in her as a registered veterinary surgeon and was in breach of legal provisions designed to safeguard human health.
“Such behaviour falls far below the standard expected of a registered veterinary surgeon, undermines public confidence in the profession and would be considered deplorable by colleagues and the public alike.
"The Committee was thus satisfied that charge 1 on its own amounts to disgraceful conduct in a professional respect.”
He added: “Acting dishonestly runs contrary to one of the most fundamental principles of the profession.
"The public need to know that they can rely on the honesty and integrity of the people to whom they entrust the care and welfare of their animals.
“Further, Dr Evans’ conduct in both incidents had the potential to undermine public confidence in the profession of veterinary surgery and bring the profession into disrepute.
"In all the circumstances, the Committee was satisfied that Dr Evans’ behaviour as reflected in charge 2 fell far short of the standard expected of a veterinary surgeon and amounted to disgraceful conduct.
“Accordingly, the Committee found proved the allegation that Dr Evans was guilty of disgraceful conduct in a professional respect.”
Having found serious professional misconduct in relation to all charges, the Committee considered what the most appropriate and proportionate sanction would be for Ms Evans’ actions and conduct.
In doing so, it considered 137 positive references and testimonials from Dr Evans’ professional colleagues and clients, poor staff morale at the practice at the time as well as compelling, exceptional evidence relating to Dr Evans’s health at the time of the two incidents.
In mitigation, the Committee considered the fact that Dr Evans had no previous disciplinary history and had a hitherto unblemished career as a veterinary surgeon; her open and frank admissions; the circumstances of pressures at work exacerbated by Dr Evans’ desire to please everyone and not let anyone down; the fact that Dr Evans was feeling very isolated; the significant insight into her conduct and its impact; effective and targeted remediation to ensure there would be no likelihood of the conduct being repeated; genuine expressions or remorse and apology; support from her employers; and the very significant number of positive testimonials.
Summing up the Committee’s decision on sanction, Mr Morris said “In all the, somewhat exceptional, circumstances of this case, the Committee was satisfied that a reprimand and a warning not to behave in this way again, would provide adequate protection to animals, as it was satisfied Dr Evans was most unlikely to ever make such a flawed set of decisions again.
“The Committee was satisfied that Dr Evans does not represent a risk to animals going forward, indeed from the character evidence it is clear that she always puts the welfare of animals first.
"She has also shown, since this episode, that she can work under pressure and not resort to making bad decisions and thus the Committee considered the wider public interest would best be served in this case by a reprimand and a warning.
“Notwithstanding the serious nature of Dr Evans' conduct, the Committee was satisfied that a fully informed member of the public would not be shocked if Dr Evans were allowed to continue to practise.
“The decision of this Committee is, therefore, that Dr Evans be reprimanded and warned about her behaviour.
"Dr Evans should, however, be under no illusion of how serious it is to have a finding of disgraceful conduct in a professional respect made against her and she should not take lightly the decision of this Committee to reprimand and warn her.”
www.rcvs.org.uk/disciplinary
Dechra Veterinary Products has launched TAF Spray (thiamphenicol), a next generation antibiotic wound spray for superficial wound infections in horses, cattle, goats, sheep and pigs.
Dechra says TAF Spray can also be used to treat infections of the claw and hoof in cattle, goats and sheep such as foot rot, interdigital dermatitis and digital dermatitis.
TAF Spray is the only licensed wound spray for horses and has a zero day meat withdrawal period for horses, cattle, goats, sheep, and 14 days for pigs.
Dechra is also highlighting the fact that TAF Spray is the only golden yellow coloured product of its kind on the market, allowing treatment areas to be distinguished clearly.
Brand Manager Emma Jennings said: “Dechra has developed TAF Spray in direct response to the research we conducted among farmers".
The research1 showed that 51% of the veterinary surgeons had used an antibiotic spray for the treatment of digital dermatitis – an infection that 92% of farmers had experienced in their livestock in the past 12 months.
Emma added: "Thiamphenicol is a highly effective antibiotic. With the brightly coloured spray format making it distinguishable from other treatments and a can that is able to be used in upright and inverted positions, we are sure that TAF Spray will become a popular product among veterinary professionals.”
TAF Spray comes in a 150ml can with a 360-degree nozzle which allows wounds to be targeted at any angle.
For further information about Dechra’s antibiotic portfolio, visit www.dechra.co.uk
Metacam 40 mg/ml solution for injection for cattle and horses contains 40 mg/ml of meloxicam, and is available in either 50 ml or 100 ml presentations. It is approved for subcutaneous or intravenous use in cattle, and intravenous use in horses.
Boehringer says the introduction comes on the back of a recent large-scale landmark study that found adding Metacam to standard antibiotic therapy for mastitis resulted in a greater first-service conception rate, fewer inseminations required to conceive and a higher probability of pregnancy by 120 days post-calving when compared to cows receiving antibiotic therapy alone1.
Boehringer Ingelheim’s technical manager Kath Aplin said: "By reducing the pain and inflammation caused by mastitis and other conditions, the use of Metacam 40 can result in improvements in cattle health and welfare, and may help limit any reduction in feed intakes. This is central to efficient herd management and productivity."
The company adds that new Metacam 40 mg/ml formulation offers a lower volume dose compared to the existing 20 mg/ml presentation, giving vets more flexibility in their use of Metacam.
EnteroZoo is a dietary supplement composed of organic mineral and purified water in a gel suspension. Enteromed says it works by binding bacterial toxins as it passes through the animal's digestive tract, thereby helping to maintain a healthy gut and intestinal balance.
Enteromed says that compared to old classic adsorbents, such as clay or charcoal, EnteroZoo can be used long-term and is gentle on an animal's intestines.
The company points to a new in-vitro study from Brighton University School of Pharmacy & Biomolecular Sciences which has shown that EnteroZoo adsorbs E. coli, Shigella and C. difficile toxins1 – common causes of gastrointestinal infection and diarrhoea.
EnteroZoo is suitable for all animals including pregnant and nursing females. It is tasteless and odourless and the company says animals generally accept it without any problems. It can be administered in various ways: directly into the mouth, mixed into feed, put on a treat, mixed in an appropriate amount of water or administered with a plastic syringe into the oral cavity.
For more information, contact: enterozoo@enteromed.co.uk, or visit: www.enterozoo.co.uk
Vikaly is indicated for the nutritional and medical management of chronic kidney disease in adult and senior cats with proteinuria, from IRIS stage 2.
The new diet delivers the same therapeutic dosage as benazepril tablets (0.5–1 mg/kg bodyweight/day).
Nutrition-wise, Vikaly is low phosphorus (0.5% as fed), has reduced protein (30% as fed), contains omega-3 fatty acids (1.2%, including 0.6% EPA & DHA) and offers high metabolisable energy (416 kcal/100g).
Virbac highlights data showing that CKD remains the leading cause of mortality in cats over five years old and affects up to 40% of feline patients over the age of ten1,2.
The company says administering daily treatment is recognised as a major issue for CKD cat owners with 45% of owners not administering treatment daily as they should and 51% of owners citing administration difficulties as the reason why3.
This new product eliminates the need to administer medication separately, which could completely transform treatment compliance, removing the risk of missed doses and reducing stress for both cats and their owners.
Virbac says that due to the pharmacokinetic profile of benazepril, which is incorporated into the kibble, at an equivalent dose Vikaly displays greater ACE inhibition than benazepril tablets4.
The rate of food consumption also does not affect plasma Benazeprilat levels, ensuring consistent treatment efficacy regardless of the cat’s feeding behaviour5.
Virbac says that in practice, this means that even if the cat being treated consumes less than 50% of their daily ration, efficacy is maintained with ACE activity similar to that of benazepril tablets.
Benazepril has a wide therapeutic margin, tolerated to 20x the minimum effective dose (10mg/kg) for 52 weeks, with the first signs of toxicity being reduced erythrocytes counts & ovary/oviduct weights6.
Virbac says that with Vikaly, these levels cannot be reached because the active ingredient is contained in food, which would require a cat to consume more than 10 times their daily ration.
Vikaly is presented in a 1.5kg bag, which equates to a 30 day supply for a 4.5kg cat with normal bodyweight.
It can be fed alongside wet food, providing that the cat consumes at least 50% of their daily ration before being given the wet food.
The daily ration can also be administered in several smaller meals throughout the day, to accommodate the individual preferences of the cat and to promote consistent food intake.
Vikaly is a prescription diet.
Zenalpha provides restraint, sedation and analgesia during non-invasive, non-painful or mildly painful procedures and examinations intended to last no more than 30 minutes2.
It is administered intramuscularly and takes effect within 5-15 minutes1, 2.
Dechra says patients also recover more rapidly2, potentially avoiding hospitalisation and allowing them to get home sooner.
Zenalpha contains the active ingredients 0.5 mg/ml medetomidine hydrochloride and 10mg/ml vatinoxan hydrochloride.
Medetomidine is an alpha-2 agonist used for its sedative and analgesic properties.
Vatinoxan is a peripherally selective alpha-2 antagonist which Dechra says has limited penetration across the blood-brain barrier, so it works to antagonise only the alpha-2 receptors located in the periphery, reducing cardiovascular side effects without impacting the quality of sedation or analgesia.
In a study of 223 dogs1 comparing a traditional alpha-2 agonist with Zenalpha, Zenalpha was found to minimise cardiovascular side effects while preserving reliable sedation and analgesia.
Claire Westoby, brand manager at Dechra said: ‘The next generation of alpha-2 agonists have evolved to provide the same effective and reliable sedation and analgesia, but with reduced cardiovascular side effects and a reduced chance of vomiting.
"This improves the sedation experience for the canine patient, as well as reducing the associated stress commonly experienced by veterinary teams and dog owners.”
Matt Gurney FRCVS, an RCVS and EBVS European Specialist in Veterinary Anaesthesia and hospital director at Anderson Moores, said: “It is really exciting to see the launch of an innovative new product, especially one with a unique mechanism of action that will improve the sedation experience for the vet team and our patients.
"Zenalpha not only provides a solution to cases where IV placement is not possible and a rapid onset IM option is required, but it also offers a rapid and complete recovery which ensures that dogs can be reunited with their owners and return home as soon as possible.”
Zenalpha is presented in a 10 ml glass vial in individually packed cardboard boxes.
For more information: www.dechra.co.uk/zenalpha or contact your local Dechra territory manager.
To watch Matt Gurney’s ‘Zennovation in sedation – the next generation of alpha-2 agonists’: www.dechra.co.uk/academy.
On 23rd March, the Government demanded that the majority of public-facing businesses close their doors. Veterinary surgeries, however, have been exempted and are allowed to remain open.
However, the number of clients seen face-to-face should be kept to an absolute minimum and veterinary teams must insist on strict social distancing measures at all times.
In addition, the RCVS/BVA say that:
The College has updated its FAQs for veterinary professionals, which can be found here: https://www.rcvs.org.uk/setting-standards/advice-and-guidance/coronavirus-covid-19/
The BVA is now developing some further guidance to provide examples of what constitutes routine, urgent and emergency care.